

1 Pneumolysin is responsible for differential gene expression and modifications in the
2 epigenetic landscape of primary monocyte derived macrophages.

3

4 J. Cole^{1,2,3,4}, A. Angyal¹, R. D.Emes⁵, T.J. Mitchell⁷, M.J. Dickman⁴, D.H. Dockrell⁸

5 1) Department of Infection, immunity & Cardiovascular Diseases, University of
6 Sheffield,

7 2) Sheffield Teaching Hospitals NHS FT

8 3) The Florey Institute, University of Sheffield

9 4) Department of Chemical & Biological Engineering, University of Sheffield,

10 5) Advanced Data Analysis centre, University of Nottingham,

11 6) School of Veterinary Medicine and Science. University of Nottingham,

12 7) Institute of Microbiology and Infection, University of Birmingham

13 8) MRC Centre for Inflammation Research, University of Edinburgh

14

15

16 **Abstract:**

17 Epigenetic modifications regulate gene expression in the host response to a
18 diverse range of pathogens. The extent and consequences of epigenetic modification
19 during macrophage responses to *Streptococcus pneumoniae*, and the role of
20 pneumolysin, a key *Streptococcus pneumoniae* virulence factor, in influencing these
21 responses, are currently unknown. To investigate this, we infected human monocyte
22 derived macrophages (MDMs) with *Streptococcus pneumoniae* and addressed
23 whether pneumolysin altered the epigenetic landscape and the associated acute
24 macrophage transcriptional response using a combined transcriptomic and proteomic
25 approach. Transcriptomic analysis identified 503 genes that were differentially
26 expressed in a pneumolysin-dependent manner in these samples. Pathway analysis
27 highlighted the involvement of transcriptional responses to core innate responses to
28 pneumococci including modules associated with metabolic pathways activated in
29 response to infection, oxidative stress responses and NF κ B, NOD-like receptor and
30 TNF signalling pathways. Quantitative proteomic analysis confirmed pneumolysin-
31 regulated protein expression, early after bacterial challenge, in representative
32 transcriptional modules associated with innate immune responses. In parallel,
33 quantitative mass spectrometry identified global changes in the relative abundance of
34 histone post translational modifications (PTMs) upon pneumococcal challenge. We
35 identified an increase in the relative abundance of H3K4me1, H4K16ac and a
36 decrease in H3K9me2 and H3K79me2 in a PLY-dependent fashion. We confirmed
37 that pneumolysin blunted early transcriptional responses involving TNF- α and IL-6
38 expression. Vorinostat, a histone deacetylase inhibitor, similarly downregulated TNF
39 production, reprising the pattern observed with pneumolysin. In conclusion,
40 widespread changes in the macrophage transcriptional response are regulated by

41 pneumolysin and are associated with global changes in histone PTMs. Modulating
42 histone PTMs can reverse pneumolysin-associated transcriptional changes
43 influencing innate immune responses, suggesting that epigenetic modification by
44 pneumolysin plays a role in dampening the innate responses to pneumococci.

45

46 **Author summary:**

47 Pneumolysin is a toxin that contributes to how *Streptococcus pneumoniae*, the
48 leading cause of pneumonia, causes disease. In this study, the toxin alters gene
49 expression in immune cells called macrophages, one of the first lines of defence
50 against bacteria at sites of infection. Modulation involved multiple immune responses,
51 including generation of chemical signals coordinating responses in immune cells
52 termed cytokines. In addition, changes were observed in histone proteins that are
53 involved in controlling gene expression in the cell. Pneumolysin reduced early
54 production of the cytokine TNF- α and a medicine vorinostat that modifies these
55 'epigenetic' histone modifications had a similar affect, suggesting epigenetic
56 mechanisms contribute to the ability of pneumolysin to reduce immune responses.

57

58 **Introduction:**

59 Pneumolysin (PLY) is one of the key virulence factors of *S. pneumoniae* (the
60 pneumococcus), the leading cause of community-acquired pneumonia (Kadioglu et al.
61 2008) and is present in the majority of clinical isolates causing invasive pneumococcal
62 disease (IPD) (Gray, Converse, and Dillon 1980; D.-K. Hu et al. 2015). Pneumolysin
63 is a cholesterol-dependent cytolysin and part of a family of toxins expressed in Gram-
64 positive bacteria (Tweten 2005). It is a 53 kDa protein that contains four domains
65 (Walker et al. 1987). One mechanism of action is through pore formation (van Pee et
66 al. 2017) but increasingly it is recognized to mediate additional actions independent of
67 the ability to form pores (Bewley et al. 2014).

68 In murine models of bacteraemia PLY sufficient mutants are associated with
69 increased lethality compared to PLY deficient mutants, linking the toxin to virulence
70 (Benton, Everson, and Briles 1995). Furthermore, the transmission of *S. pneumoniae*
71 between hosts has been linked to the presence of inflammation in the nasopharynx
72 and pneumolysin has been shown to promote inflammation, increase transmission
73 and foster the survival *ex vivo* of *S. pneumoniae* (Zafar et al. 2017). It has been also
74 suggested that pneumolysin facilitates blood stream invasion by *S. pneumoniae* (D.-
75 K. Hu et al. 2015). This highlights its importance as a key virulence factor of *S.*
76 *pneumoniae* due to its role in the transmission of *S. pneumoniae* between hosts, in
77 the progression from nasopharyngeal colonisation to invasive pneumococcal disease,
78 the stimulation of inflammation and its cytotoxic effects (Kadioglu et al. 2008).

79 Pneumolysin has been shown to alter a variety of immune responses. For
80 example it has been demonstrated to both activate the classical complement pathway
81 (Paton, Rowan-Kelly, and Ferrante 1984) as well as play a role in complement evasion
82 (Quin, Moore, and McDaniel 2007). Pneumolysin has been associated with stimulation

83 of NLRP3 and potentially other inflammasome components (McNeela et al. 2010; R.
84 Fang et al. 2011). In human monocytes it is associated with production of tumour
85 necrosis factor alpha (TNF- α) and interleukin (IL-1 β (Houldsworth, Andrew, and
86 Mitchell 1994). Pneumolysin has been shown to be responsible for the differential
87 expression of multiple genes in undifferentiated THP-1 cells, a monocytic cell line,
88 (Rogers et al. 2003) but its impact on gene expression in primary macrophages has
89 not been established in detail. More recently, pneumolysin has been shown to bind
90 the mannose receptor C type 1 in mouse alveolar macrophages leading to diminished
91 pro-inflammatory cytokine release and enhanced bacterial survival (Subramanian et
92 al. 2019).

93 The subversion of the host immune system is one of the key components of
94 bacterial pathogenesis. Microorganisms can highjack host gene expression to their
95 benefit (Eskandarian et al. 2013; Hamon et al. 2007; Rolando et al. 2013). Epigenetic
96 mechanisms such as histone post-translational modifications (PTMs) have been
97 shown to regulate gene transcription (Berger 2007; Jenuwein and Allis 2001).
98 Moreover, they can be modulated by a number of different bacterial components (Cole
99 et al. 2016). Experiments using both *Legionella pneumophila* (Rolando et al. 2013),
100 and *Listeria monocytogenes* (Eskandarian et al. 2013) have shown that bacterial
101 interaction with the THP-1 monocytic cell line also modifies histone PTMs. In the case
102 of *Listeria monocytogenes*, Listeriolysin O, a pore-forming cytolysin similar to PLY, is
103 secreted causing dephosphorylation at serine 10 of histone H3 and reduction in the
104 levels of acetylated H4 in THP-1 cells. In HeLa cells these changes altered the
105 transcriptional profile, which was associated with a decrease in IL-6 and other genes
106 involved in innate immune responses (Hamon et al. 2007). This supports the

107 hypothesis that bacteria alter the epigenetic profile of the host cell as a strategy for
108 immune subversion, limiting the inflammatory response to increase their survival.

109 The consequences of epigenetic changes during acute bacterial infections are,
110 however, not fully understood. The aim of this study was to investigate the
111 consequences and mechanism underpinning the ability of pneumolysin to modulate
112 translational responses to *S. pneumoniae* using primary human macrophages. We
113 found that pneumolysin modulates a broad range of immune transcriptional responses
114 in macrophages and differential protein expression analysis also confirmed changes
115 in key transcriptional modules. Moreover, we identified global changes in the
116 abundance of histone PTMs in MDMs in a pneumolysin dependent manner. We
117 illustrate that one key pneumolysin-regulated immune response, early TNF- α
118 production is also altered by chemical manipulation of histone PTMs.

119

120 **Results:**

121 **Pneumolysin shapes the macrophage transcriptome in response to**
122 **pneumococci.**

123
124 Transcriptional responses to Gram-positive bacteria occur rapidly and are well
125 developed after three hours of bacterial challenge (Hamon et al. 2007)(Rogers et al.
126 2003). Therefore, we initially analyzed transcriptional changes in monocyte-derived
127 macrophages (MDMs) three hours after bacterial challenge with either wild-type or a
128 pneumolysin deficient (Δ PLY) strains. We confirmed that intracellular viability of
129 pneumococci was equivalent at this time between wild-type and Δ PLY strains (Fig S1),
130 thereby excluding potential confounding by different levels of vita-pathogen-
131 associated molecular pattern (Sander et al. 2011).

132 We identified 1872 probe-sets that were differentially expressed in response to
133 bacterial challenge with either strain (F value <0.05) and 1553 after multiple test
134 correction false discovery rate (FDR <0.05). Next, we calculated moderated t tests for
135 each infection, as shown in the Volcano plots in Figure 1. The analysis identified 503
136 probe-sets which are differentially expressed in a pneumolysin-dependent manner
137 and 234 in an independent manner (summarised Fig S2). To provide further insight
138 into the pneumolysin-dependent differential gene expression in MDMs we undertook
139 pathway analysis of the differentially expressed genes.

140

141 **Pathway analysis of differentially expressed genes:**

142 Gene Ontology (GO) pathway analysis demonstrated that the top ten enriched
143 terms in the pneumolysin-dependent differentially expressed genes were
144 predominantly related to cell metabolism (Fig S3). However, there were also a number
145 of terms relating to cellular responses to “stress” (17 in the *S. pneumoniae* challenge

146 and 15 in the Δ PLY mutant) and in particular to oxidative stress responses. The
147 volcano plots for the differentially expressed genes belonging to the GO term for
148 oxidative stress response were plotted for each strain (Fig 2). These results
149 highlighted that the differentially expressed genes were predominantly upregulated.
150 Moreover, the TNF, heme oxygenase 1 (HMOX1) and prostaglandin-endoperoxide
151 synthase 2 (PTGS2) genes were strongly upregulated.

152 In addition to performing Gene ontology analysis we also analysed the
153 differentially expressed genes using eXploring Genomic Relations (XGR) which
154 performs hypergeometric enrichment analysis with background correction using the
155 expression of monocyte derived macrophage cells to give a more cell type specific
156 analysis. Canonical pathway analysis was performed for genes whose expression was
157 upregulated in response to challenge with *S. pneumoniae* (adjusted p value <0.05).
158 This revealed 36 over-represented pathways (Table S1). Importantly this
159 demonstrated that both the TNF and the NF κ B signalling pathways were enriched.
160 Analysis of the 2-fold downregulated terms did not reveal any enriched canonical
161 pathways.

162 The analysis of the differentially expressed genes whose expression was up-
163 regulated by greater than 2-fold in response to challenge with the Δ PLY mutant also
164 revealed that the pathways for TNF, NF κ B and CD40 signalling were significantly over-
165 represented (Table S2). This highlights the importance of these pathways in the
166 response to bacterial challenge. It also suggests that the increase in pro-inflammatory
167 signals being released in particular TNF is independent of PLY. Of note, we observed
168 a 6-fold increase in the TNF mRNA in response to Δ PLY but only 4-fold increase in
169 response to the parent strain (Fig 2).

170 **Label-free quantitative proteomic analysis:**

171 Having established that there was a transcriptional difference in the host cell
172 response following challenge with *S. pneumoniae* or Δ PLY, further studies were
173 performed to examine the effects of *S. pneumoniae* on the proteome of MDMs.

174 Label free quantitative mass spectrometry was used to identify differentially
175 expressed proteins following challenge with *S. pneumoniae* or Δ PLY. We identified
176 1807 proteins in samples challenged with *S. pneumoniae* and 1862 in those
177 challenged with Δ PLY. On average we identified 1812 proteins in each of the 12
178 samples from 4 biological replicates that we analysed. Of these, we identified 32 that
179 were differentially expressed between the three conditions with an F statistic value of
180 less than 0.05 (summarised in Table 1). The results show that 16 proteins are
181 differentially expressed in response to infections with *S pneumoniae*, and 22 in
182 response to Δ PLY. Eight proteins were differentially expressed in a pneumolysin-
183 dependent manner, these included serine / threonine protein kinase 1, also known as
184 the oxidative stress response 1 protein (OXSR1) and Ubiquitin domain-containing
185 protein 1 / 2 (UBTD2), and 9 were common to both bacterial strains, including Galectin
186 3 binding protein which is involved in the host immune responses (Breuilh et al. 2007)
187 and the 26S proteasome non-ATPase regulatory subunit 5 (PSMD5). Several of the
188 differentially expressed proteins identified such as PSMD5, UBTD2 and Ubiquitin
189 conjugation factor E4 A (UBE4A) are involved in protein turn-over involving a number
190 of pathways known to be important in the regulation of host immune responses (H. Hu
191 and Sun 2016).

192

193

194

195 Table 1: Differentially expressed proteins at 6 h following challenge with *S pneumoniae*

196 or Δ PLY.

	MI vs <i>S pneumoniae</i>			MI vs Δ PLY				
Majority Protien ID	logFC	P.Value	adj.P.Val	logFC	P.Value	adj.P.Val	protein name	Gene name
P23219;A0A087X296	-2.83E+00	1.96E-03	6.42E-03	-1.67E+00	1.70E-02	2.60E-02	Prostaglandin G/H synthase 1	PTGS1
O95747;C9JIG9	-2.36E+00	2.39E-05	3.82E-04	-1.03E+00	4.02E-02	5.59E-02	Serine/threonine-protein kinase OSR1	OSR1
P51531;A0A0U1RQZ9;F6VDE0;Q9HBD4;A0A0A0MT49;P51532;A0A0U1RRD6;A0A0U1RRF8;A0A0A0MS5;F6UH26;A0A0U1RQU0;A0A0U1RR09;F6XE55;A0A0U1RQW7;A0A0U1RRN2;B1ALG1;A0A0U1RR83;A0A0U1RQX3;F6T8Q0;B1ALG2;A0A0U1RR26;A0A0U1RRG6;B4DNT1;B1ALF6	-3.69E+00	3.61E-05	3.85E-04	-5.99E-01	4.37E-01	4.99E-01	Probable global transcription activator SNF2L2 / Transcription activator BRG1	SMARCA2 / SMARCA4
Q08380;K7EJY8;K7ESM3;K7EKQ5;K7EP36	-2.36E+00	1.57E-04	1.26E-03	-1.94E+00	1.30E-03	2.96E-03	Galectin-3-binding protein	LGALS3BP
Q9HAC8;Q8WUN7	2.84E+00	3.87E-04	2.48E-03	6.83E-01	2.49E-01	2.95E-01	Ubiquitin-domain-containing protein 1 / 2	UBTD2
P36871	-2.19E+00	5.77E-03	1.42E-02	-2.69E+00	1.02E-04	8.14E-04	Phosphoglucomutase-1	PGM1
Q709C8	-1.83E+00	2.00E-03	6.42E-03	-2.06E+00	1.78E-04	1.04E-03	Vacuolar protein sorting-associated protein 13C	VPS13C
M0R300;M0R0P8;Q13459	-1.27E+00	2.17E-02	4.09E-02	-2.05E+00	6.71E-03	1.13E-02	Unconventional myosin-Ib	MYOB9B
A0A0C4DG89;Q7L014;D6RJA6	1.69E+00	1.83E-03	6.42E-03	6.49E-01	1.74E-01	2.15E-01	Probable ATP-dependent RNA helicase DDX46	DDX46
P46087	1.62E+00	1.39E-03	6.42E-03	6.09E-02	9.07E-01	9.32E-01	Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase	NOP2
O60826	2.54E+00	4.21E-03	1.23E-02	9.88E-01	1.50E-01	1.92E-01	Coiled-coil domain-containing protein 22	CCDC22
Q9Y5X2	1.63E+00	1.18E-02	2.47E-02	-1.22E+00	2.31E-02	3.36E-02	Sorting nexin-8	SNX8

Q5U5X0	1.66E+00	4.79E-03	1.28E-02	1.47E+00	5.25E-03	9.57E-03	Complex III assembly factor LYRM7	LYRM7
R4GMN1;Q8NHP6	-1.29E+00	6.85E-03	1.57E-02	-4.13E-02	9.32E-01	9.32E-01	Motile sperm domain-containing protein 2	MOSPD2
A0A087WUZ3;Q01082	2.52E+00	1.73E-03	6.42E-03	2.02E+00	2.02E-03	4.05E-03	Spectrin beta chain, non-erythrocytic 1	SPTBN1
O95336;M0R261	-1.18E+00	1.23E-02	2.47E-02	-6.15E-02	8.98E-01	9.32E-01	6-phosphogluconolactonase	PGLS
Q16401;F2Z3J2	2.76E+00	1.92E-06	6.14E-05	1.90E+00	6.73E-04	1.66E-03	26S proteasome non-ATPase regulatory subunit 5	PSMD5
Q14139	-1.69E+00	5.47E-02	8.34E-02	3.92E+00	7.24E-05	7.72E-04	Ubiquitin conjugation factor E4 A	UBE4A
O95865;A0A140T971;Q5SSV3;Q5SRR8	-1.48E+00	3.31E-02	5.88E-02	-2.13E+00	2.95E-04	1.09E-03	N(G),N(G)-dimethylarginine dimethylaminohydrolase 2	DDAH2
P26639	-1.42E+00	4.11E-02	6.93E-02	-2.12E+00	5.38E-03	9.57E-03	Threonine-tRNA ligase, cytoplasmic	TARS
Q9BXW7	-8.74E-01	2.29E-01	2.62E-01	-2.79E+00	2.39E-04	1.09E-03	Halocid dehalogenase-like hydrolase domain-containing 5	HDHD5
F8W031;F8VXJ7;Q9Y2B0;F8W1K5	-8.82E-01	5.89E-02	8.56E-02	6.65E-01	1.50E-01	1.92E-01	Protein canopy homolog 2	CNPY2
H0Y8C3;Q9NZJ7	-8.67E-01	8.03E-02	1.08E-01	-2.88E+00	2.34E-05	3.75E-04	Mitochondrial carrier homolog 1	MTCH1
Q92616	-7.39E-01	1.55E-01	1.91E-01	-1.79E+00	6.15E-04	1.66E-03	eIF-2-alpha kinase activator GCN1	GCN1
O00115;K7ENE5	-6.51E-01	9.23E-02	1.18E-01	8.86E-02	8.15E-01	9.00E-01	Deoxyribonuclease-2-alpha	DNASE2
H0Y8X4;O43598	-2.52E-01	7.29E-01	7.52E-01	-2.74E+00	3.39E-04	1.09E-03	2'-deoxynucleoside 5'-phosphate N-hydrolase 1	DNPH1
Q92508	2.29E-01	7.61E-01	7.61E-01	-2.36E+00	1.96E-04	1.04E-03	Piezo-type mechanosensitive ion channel component 1	PIEZ01
E9PF10;O75694	3.86E-01	5.89E-01	6.29E-01	2.01E+00	1.53E-03	3.27E-03	Nuclear pore complex protein Nup155	NUP155
P62244;I3L3P7	4.58E-01	2.43E-01	2.68E-01	1.09E+00	7.51E-03	1.20E-02	40S ribosomal protein S15a	RPS15A
Q495G5;Q8IVH4;D6RIS5	7.06E-01	1.79E-01	2.13E-01	1.94E+00	6.61E-04	1.66E-03	Methylmalonic aciduria type A protein, mitochondrial	MMAA

198 **Pneumolysin is responsible for changes in the relative abundance of histone**
199 **post-translational modifications:**

200 Having defined a pneumolysin-dependent alteration of the macrophage
201 transcriptome and proteome in response to *S. pneumoniae*, we sought next to
202 establish if PLY also influenced epigenetic changes in response to *S. pneumoniae*.
203 Quantitative mass spectrometry was used to identify changes in the global abundance
204 of histone PTMs following challenge with *S. pneumoniae* or Δ PLY. Focussing on the
205 most abundant PTMs, methylation and acetylation, on histones H3 and H4, in MDMs
206 in response to bacterial challenge we identified 94 different peptide proteoforms and
207 18 were found to change in response to bacterial challenge (Fig 3 & 4). A subset of
208 these changes were PLY-dependent, since they were significantly altered in *S.*
209 *pneumoniae* in comparison to the Δ PLY mutant (Table 2). These included significant
210 increases in the relative abundance of H3K4me1 and H3.3K36me2 following
211 challenge with *S. pneumoniae* in comparison to Δ PLY. In addition, we observed
212 decreases in the relative abundance of H3K9me2, H3K27me2 and H3K79me2 in a
213 pneumolysin-dependent manner compared to both mock infected (MI; blue) and Δ PLY
214 (Fig 3). Moreover, there was a pneumococcal associated PLY-independent increase
215 in the level of H3K27me2K36me2 and a reciprocal drop in H3K27me3K36me1. We
216 noted an increase in the relative abundance of H3.3K36me2 in a PLY dependent
217 manner and an increase in the relative abundance of H3K23ac and an increase in
218 H3.3K27me2K36me1 with a reciprocal drop in H3.3K27me2K36me2 in response to
219 both bacterial challenges.

220
221

222 Table 2: Summary of the significant changes in relative abundance of histone PTMs
223 identified following bacterial challenge

Histone PTM	<i>S. pneumoniae</i>	Δ PLY
H3K4me1	Up	Down
H3K9me2	Down	Up
H3K23ac	Up	Up
H3K27me2	Down	Up
H3K27me2K36me2		Up
H3K27me3K36me1		Down
H3.3K27me2K36me1	Up	Up
H3.3K27me2K36me2	Down	Down
H3.3K36me2	Up	Down
H3K79me2	Down	Up

224
225 Further analysis of histone H4 showed a significant increase in the
226 abundance of acetylation on K16 (H4K16ac) in response to infection with either strain
227 (Fig 4). In addition, there was also a decrease in the dimethylated form of K20
228 (H4K20me2) and a reciprocal increase in the monomethylated form (H4K20me1) in a
229 pneumolysin-dependent manner.

230 **Pneumolysin blunts inflammatory signalling during early infection:**

231 In order to establish the consequences of these changes to the transcriptome
232 and epigenome, we next selected one prominent immune signature regulated by
233 pneumolysin, TNF- α expression, and established this as a key component of the early
234 immune response to *S. pneumoniae* (Jones et al. 2005). Using qRT-PCR we
235 measured the abundance of TNF α mRNA in infected MDMs. There was a significant
236 increase in the TNF α mRNA level following infection with the PLY deficient mutant but
237 not the parent strain or the reconstituted mutant (Fig 5A). Next, we measured the
238 amount of secreted of TNF α in MDM supernatants following 3 h of bacterial challenge

239 (Fig 5B). We found that TNF α levels were significantly higher following challenge with
240 the Δ PLY mutant suggesting that PLY initially blunts TNF- α expression.

241 Finally, we measured the concentration of TNF α over time using ELISA
242 assays to determine if this initial anti-inflammatory effect was maintained (Fig 5C). The
243 results showed that the difference seen in the release of TNF- α , was only observed at
244 an early time window, 3-5 h after exposure to bacteria. This suggests that the anti-
245 inflammatory effect of pneumolysin only plays a role over a defined time period.

246

247 **Histone deacetylase inhibitors reduce TNF α cytokines in response to infection:**

248 Having previously demonstrated that pneumolysin both modifies
249 macrophage transcriptome and epigenome we next tested if epigenetic modifications
250 could alter key PLY-associated immune responses. As a proof of concept, we pre-
251 treated MDMs with the histone deacetylase inhibitor (HDACi) vorinostat (SAHA) or
252 vehicle control (DMSO) following challenge with *Streptococcus pneumoniae* or Δ PLY
253 mutant and quantified TNF α release (Fig 6). As previously shown, challenge with the
254 Δ PLY mutant strain resulted in significantly increased TNF α levels as compared to the
255 parental strain, but this level was significantly decreased in the Δ PLY mutant
256 challenged cells by pre-treatment with vorinostat. This suggests that the epigenetic
257 modifications we observed as being induced by PLY exposure could have functional
258 consequences to immune responses, as illustrated for TNF α .

259

260 **Discussion:**

261 Using a range of systems level approaches we have demonstrated that
262 pneumolysin exerts a strong influence over the host response to *S. pneumoniae* at the
263 transcriptomic, proteomic and epigenetic level. We have shown that 503 probes were

264 differentially expressed in pneumolysin-dependent manner in association with global
265 pneumolysin dependent changes in histone PTMs. These changes are associated
266 with widespread changes in macrophage metabolism, oxidative stress responses and
267 cytokine signalling and result in differential expression of key immune proteins,
268 including TNF- α and IL-6. Crucially we show that use of a HDAC inhibitor to modify
269 the epigenome is sufficient to reprise the reduction in TNF- α identified as occurring in
270 response to pneumolysin.

271 Our results on the transcriptional response of macrophages to pneumolysin are
272 consistent with previous transcriptomic analysis in undifferentiated THP-1 cells that
273 showed 142 genes to be differentially expressed in a PLY dependent manner and 40
274 to be PLY independent (Rogers et al. 2003). Our study in primary cells, identifies many
275 more genes differentially regulated enabling more in-depth analysis of changes at a
276 pathway level. A number of differentially expressed genes are involved in the immune
277 response such as TNF and HMOX1. Pathway analysis of the differentially expressed
278 probes highlighted the importance of metabolic pathways in response to infection, and
279 in particular the role for oxidative stress responses. The host's oxidative stress
280 responses have been highlighted as playing a key role in the host response to *S*
281 *pneumoniae* in lung epithelial cells (Zahlten et al. 2015). Importantly, this module is
282 upregulated in alveolar macrophages (AM) and plays a key role in preserving
283 responses such as phagocytosis which may otherwise be altered by dysregulated
284 oxidative stress in AM and MDM (Bewley et al. 2014; Belchamber et al. 2019).
285 Furthermore, nuclear factor erythroid 2 (NRF2), the master regulator of antioxidant
286 responses, plays a pivotal role in the protection against lung injury (Zhao et al. 2017),
287 reduces lung inflammation after intratracheal instillation of LPS and decreases
288 mortality in systemic models of inflammation (Thimmulappa et al., 2016). Crucially,

289 NRF2-regulated pathways are amenable to therapeutic manipulation as evidenced by
290 improved AM phagocytosis in patients with chronic obstructive pulmonary disease
291 following *ex vivo* treatment with NRF2 agonists and also in a mouse model of cigarette
292 smoke associated impairment of bacterial clearance in the lung (Harvey et al. 2011).
293 The XGR pathway analysis following bacterial challenge further highlighted NFkB,
294 NOD-like receptor and TNF signalling as enriched pathways emphasising their
295 importance in the host's response to bacteria.

296 The label-free quantitative proteomic analysis revealed a small number of
297 significantly differentially expressed proteins, but substantiated involvement of several
298 of the pathways identified at the transcriptomic pathway level. Examples of proteins
299 linked to these pathways included an increase in the coiled-coil domain containing
300 protein 22 (CCDC22), that plays an essential role in NFkB signalling and whose
301 depletion leads to blockade of signalling (Starokadomskyy et al. 2013). As an example
302 of a protein downregulated we noted that the oxidative stress response protein 1
303 (OXSR1) involved in the oxidative stress response (W. Chen, Yazicioglu, and Cobb
304 2004) was decreased in a PLY-dependent manner.

305 The proteomic analysis also identified a number of differentially expressed
306 proteins that are involved in regulating gene transcription and protein translation. The
307 probable global transcription activator SNF2L2 / Brahma and the transcription
308 activator Brahma-related gene 1 proteins were decreased in PLY dependent manner.
309 They are associated with regulation of gene transcription by chromatin remodelling (B.
310 G. Wilson and Roberts 2011). The ATP dependent RNA helicase DDX46 which is
311 associated with pre-mRNA splicing (Will et al. 2002) was also increased in a PLY
312 dependent manner. In addition, we observed an increase in the probable 28S rRNA
313 (cytosine(4447)-C(5))-methyltransferase encoded for by the NOP2 gene which has

314 been shown to be associated with the assembly of the large subunit of the ribosome
315 and may play a role in cell cycle and proliferation (Sloan, Bohnsack, and Watkins
316 2013). In summary, the quantitative proteomic analysis identified a number of
317 pneumolysin-dependent differentially expressed proteins involved in the regulation of
318 gene transcription, protein translation, and modulation of signalling pathways such as
319 the NFkB pathway, which are predicted to regulate innate immune responses to
320 bacteria.

321 Although the absolute number of differentially expressed proteins is small, these
322 results are in keeping with a number of previously published proteomic studies. In a
323 study of THP-1 cells infected with *Mycobacterium tuberculosis* only 61 proteins were
324 found to be differentially regulated (P. Li et al. 2017). In a study of alveolar
325 macrophages infected with porcine reproductive and respiratory syndrome virus only
326 95 proteins were differentially expressed (Qu et al. 2017). Furthermore, this study has
327 used primary cells and one of the reasons for the relatively small number of
328 differentially expressed proteins may be the large differences between the biological
329 replicates such that small differences in protein abundances following infection may
330 not reach statistical significance. Several studies have shown only modest correlation
331 between transcriptomic and proteomic datasets (Stare et al. 2017; G. Chen et al. 2002;
332 Pascal et al. 2008; Ghazalpour et al. 2011), which might further explain the small
333 number of differentially expressed proteins. Moreover, the transition from altered
334 transcriptional response to altered proteome may take longer than the 6 hour time
335 point studied. Indeed, in the study of proteomic response to *M. tuberculosis* and
336 pathogenic porcine reproductive and respiratory syndrome virus both authors used a
337 24 hour time point (H. Li et al. 2017; Qu et al. 2017). It is also possible that many of

338 the differentially expressed proteins are of relatively low abundance and therefore not
339 readily detected using a shotgun proteomics approach.

340 Finally, the quantitative mass spectrometry analysis of histone PTMs in response
341 to *S. pneumoniae* was used to identify and quantify 94 different peptide proteoforms.
342 Of these, there were 5 whose relative abundance changed in a pneumolysin
343 dependent manner. This is to our knowledge the first time that this approach has been
344 applied to study the changes in relative abundance of histone PTMs in primary MDMs
345 in response to *S. pneumoniae*. The advantages of mass spectrometry analysis used
346 in this study were emphasised by the identification of combinatorial marks on both H3
347 and H3.3 that would not have been possible using antibody-based approaches.
348 Interestingly several of these modifications are associated with activating or
349 repressing gene transcription. Although some histone PTMs are well characterised in
350 a number of systems, their exact function in the context of infections is yet to be fully
351 described. It is likely to vary between cell types. Furthermore, individual PTMs will not
352 act in isolation but rather be part of a combinatorial code fine tuning responses to
353 environmental stressors, such as to bacterial infection and at later time points after
354 exposure to consequences such as DNA damage. Nevertheless, in light of the
355 changes observed in response to challenge with *S. pneumoniae* (e.g. increases in
356 H3K4me1, H3K23ac or H4K16ac and decreases in H3K9me2 or H3K79me2) it is
357 possible that these changes represent the removal of repressive marks and the
358 increase in marks associated with active gene transcription. This would allow fine
359 tuning of the innate immune host response to bacteria to occur. This highlights the
360 important role played by PTMs in the response to infection and therefore offer the
361 potential for the novel use of therapeutic approaches involving immunomodulation of

362 host responses through the use of emerging classes of drugs that target the enzymes
363 that regulate these histone PTMs.

364 The functional consequences of the net changes to transcriptional responses
365 involving inflammatory cell signalling and regulation of protein expression were
366 examined focusing on TNF- α as an exemplar early response cytokine that plays a key
367 role against *S. pneumoniae* (Jones et al. 2005). We selected this cytokine since PLY
368 induced a significant temporal reduction in production of TNF- α , in conjunction with
369 decreased production of IL-6. Our demonstration that pneumolysin inhibits the early
370 production of TNF- α is consistent with the findings others have reported in dendritic
371 cells and murine AM (Subramanian et al. 2019). We were able to demonstrate that
372 changes in the epigenetic landscape are sufficient to reverse the maximal induction of
373 TNF- α production observed following challenge with the PLY-deficient mutant. These
374 experiments, using a HDACi, suggest that blunting of TNF- α release by MDM following
375 challenge with a pneumococcal strain expressing PLY could be mediated through
376 epigenetic mechanisms. This is important since early response cytokine generation is
377 critical to the outcome of infection in *S. pneumoniae* and any modulation through
378 reshaping the epigenetic landscape would be anticipated to have major consequences
379 to the outcome of infection. Of note, the HDAC inhibitor Cambinol has been shown to
380 inhibit TNF and IL-6 secretion in bone marrow-derived macrophages stimulated with
381 LPS and was associated with greater survival in a murine lethal endotoxemia model
382 and in response to *Klebsiella pneumoniae* challenge (Lugrin et al. 2013). In this case
383 the therapeutic intervention was thought to limit excessive cytokine responses
384 whereas in the case of PLY we would suggest it may limit early cytokine responses
385 required to enhance early pathogen control. This emphasizes that in line with other

386 aspects of host modulation through epigenetic manipulation would require careful
387 calibration.

388

389 In summary our findings using a range of systems levels approaches show that
390 pneumolysin modifies the early host response of macrophages to *S. pneumoniae*
391 through modification of inflammatory responses, resistance to oxidative stress and
392 metabolic responses. We observe that these transcriptional responses and the
393 differential protein expression are associated with global changes in histone PTMs.

394 We show alteration of the epigenetic landscape has functional consequences to key
395 immune responses such as TNF- α production and suggest that PLY exerts these
396 affects through epigenetic modulation and regulation of histone acetylation status. Our
397 results also hint at a potential route by which these early host responses can be altered
398 to improve responses to infection through the use of agents that modulate the
399 enzymes that induce the signature pathogen-mediated epigenetic marks that
400 adversely impact host responses.

401

402

403 **Materials and methods:**

404 **Bacterial Strains:**

405 *Streptococcus pneumoniae* serotype 2 strain D39 (D39), the isogenic
406 pneumolysin-deficient mutant D39- Δ PLY (Δ PLY), which has a single amino acid
407 substitution in the pneumolysin sequence generating a STOP codon and the
408 reconstituted mutant PLY-D39- Δ PLY, which expresses PLY under an erythromycin
409 promoter, were kindly obtained from Prof T. Mitchell (University of Birmingham). These
410 were cultured and characterized as previously described (Bewley et al. 2014). Strains
411 were grown in brain heart infusion broth and 20% FCS to mid exponential phase (with
412 or without 1 μ g/mL erythromycin).

413

414 **MDM infection:**

415 Whole blood was obtained from healthy volunteers. Ethical approval was
416 granted by South Sheffield Regional Ethics committee (07/Q2305/7). Peripheral blood
417 mononuclear cells were separated by differential centrifugation using a Ficoll-Paque
418 gradient and differentiated into monocyte derived macrophages (MDM) for 14 d as
419 previously described in 24 well plates (Corning) (Collini et al. 2018). Bacteria were
420 washed in PBS and re-suspended in RPMI 1640 supplemented with 10% pooled
421 human immune serum (from previously vaccinated volunteers with demonstrable
422 antibody levels to serotype 2 pneumococci) (Gordon et al. 2000). MDM were
423 challenged with either opsonised D39, Δ PLY or PBS, at a MOI of 10, rested on ice for
424 1 h and incubated at 37°C in 5% CO₂ for a further 3 h (Minshull et al. 2016). For certain
425 experiments cells were treated with 3 μ M vorinostat (SAHA, Sigma) or 0.5% DMSO
426 (vehicle control) for 30 min prior to bacterial challenge and vorinostat reintroduced
427 after bacterial challenge.

428 **S. pneumoniae internalisation assay:**

429 MDM were challenged with opsonized *S. pneumoniae* for 3 h then washed
430 three times in PBS, incubated for 30 min in RPMI media (Lonza) with 40 units/mL of
431 benzylpenicillin (Sigma) and 20 mg/mL gentamicin (Sanofi). The cells were then
432 washed three times in PBS and incubated in 250 μ L of 2% saponin (Sigma) for 12 min
433 at 37°C in 5% CO₂, then 750 μ L of PBS was added, followed by vigorous pipetting.
434 The number of internalised viable bacteria were measured by counting the number of
435 colony forming units on Colombia blood agar (CBA) after 24 h incubation at 37°C in
436 5% CO₂ contained in these lysates measured in triplicate.

437 **Cytokine measurements:**

438 Supernatants were obtained from MDM challenged with bacteria and were
439 analysed as per the manufacturers protocol using either Tumour necrosis factor alpha
440 (TNF- α (Ready-set-go!TM, eBioscience)) or interleukin 6 (IL-6kit (Ready-set-go!TM,
441 eBioscience)). Briefly, 96 well ELISA plates were coated with 100 μ L of 1x capture
442 antibody overnight at 4°C, washed, and blocked in 200 μ L assay diluent for 1 h at
443 room temperature. After a wash, the supernatants were then added as were the
444 standards (recombinant human TNF- α or recombinant human IL-6) and incubated for
445 2 h at room temperature. The wells were then washed and the detection antibody
446 (biotin-conjugated anti-human TNF- α or anti-human IL-6) was added. After washing
447 100 μ L avidin-horse radish peroxidase (HRP) was added to each well for 30 min at
448 room temperature. Plates were then washed, prior to adding 100uL
449 tetramethylbenzidine substrate solution for 15 at room temperature. The reaction was
450 stopped by adding 2M sulphuric acid, the plate was then read at 450 nm using a
451 Multiskan[®] EX plate reader (Thermo Scientific), and the data analysed in GraphPad
452 Prism version 7.0c. (GraphPad Software).

453 **RNA Extraction:**

454 After 3 h of bacterial challenge, cells were washed and lysed in 600 μ L Tri
455 Reagent (Sigma) for 15min at room temperature before storing at -80 C. Ribonucleic
456 acid (RNA) extraction was performed following the manufacturers guidelines for
457 Direct-ZolTM RNA miniPrep (Zymo). Briefly, samples in Tri Reagent[®] were centrifuged
458 at 12 000g for 1 min, then the supernatant was transferred to a fresh 1.5 mL tube,
459 100% ethanol was added in a 1:1 ratio and well mixed. This was then transferred to
460 the Zymo-spinTM column, centrifuged for 1 min, then washed using 400 μ L Direct-ZolTM
461 RNA pre-wash, centrifuged again at 12 000g for 1 min, then washed in 700 μ L RNA
462 wash buffer and again centrifuged at 12 000g for 1 min. Finally the RNA was eluted
463 out in 50 μ l DNase/RNase free water.

464 **Microarray mRNA expression analysis:**

465 Affymetrix chip micro-array (Human Genome U133 plus 2.0 array, Santa Clara,
466 CA) analysis of samples from three individuals was undertaken to characterise gene
467 expression as previously described(Bewley et al. 2018). Data analysis was performed
468 as previously described (Bewley et al. 2018). Briefly, CEL files were analysed using R
469 version 3.4.0 . CEL files were read using *Simpleaffy* version 2.52.0(C. L. Wilson and
470 Miller 2005); background intensity correction, median correction and quantile probeset
471 normalisation was performed using robust multi-array average expression with the
472 help of probe sequence (GCRMA), using *AffyPLM* version 1.52.1(Bolstad et al. 2005).
473 The quality control matrix was generated using *Simpleaffy* and *AffyPLM*. Principal
474 component analysis was performed in R. The probes whose intensity were within the
475 lowest 20th centile were removed, using Dplyr version 0.7.1. Differential gene
476 expression was calculated using *Limma* version 3.32.2.

477 **Pathway analysis:**

478 Pathway analysis was performed from the differentially-expressed gene lists
479 generated. Hypergeometric tests were calculated in R, using *GO.db* version 3.4.1 to
480 search the Gene Ontology (GO) database (Ashburner et al. 2000) for molecular
481 function, cellular component, and biological process, using a p value cut off of 0.01
482 and a minimum of 3 genes. In addition, canonical pathway analysis was performed
483 using XGR (1.1.5) (H. Fang et al. 2016) using all of the differentially expressed probes
484 identified by ANOVA calculated in *Limma* as the test background.

485

486 **Real time quantitative polymerase chain reaction (RT-PCR):**

487 The abundance of TNF α mRNA in bacterial exposed and mock-infected MDM was
488 measured using qPCR. To perform cDNA synthesis a high-capacity cDNA reverse
489 transcription kit (Applied Biosystems) was used to make complementary DNA for
490 qPCR assay as per manufacturers protocol. The DNA products were quantified on
491 QuantStudio5 (Abi) using GoTaq qPCR master mix (Promega). The reactions were
492 prepared as per manufacturers protocol.

493 Primers used:

494 TNF α : Forward 5' CTCTTCTGCCTGCTGCACTTG 3'
495 Reverse 5' ATGGGCTACAGGCTTGTCACTC 3'
496 GAPDH: Forward 5' TGCACCACCAACTGCTTAGC 3'
497 Reverse 5' GGCATGGACTGTGGTCATGAG 3'
498 Actin: Forward 5' CCTTGCCGATCCGCCG 3'
499 Reverse 5' GATATCATCATCCATGGTGAGCTGG 3'

500 Fold change was calculated using Delta Delta Ct values.

501

502 **Quantitative proteomics:**

503 Protein lysates were digested with trypsin in conjunction with the Filter aided
504 separation protocol (FASP) (Wiśniewski et al. 2009). Briefly, cells were lysed in 150
505 μ L of 4% Sodium dodecyl sulphate (Sigma), 100 mM Tris HCl (Sigma) pH 7.6, 0.1 M
506 Dithiothreitol (Sigma) and quantified using a BioRad DC assay as per the
507 manufacturers protocol. 100 μ g of protein lysates were mixed with 200 μ L of 8 M
508 urea dissolved in triethylammonium bicarbonate (TEAB) and added to the filter
509 mounted in 11.5 mL low-bind Eppendorf. The tubes were centrifuged at 14 000 g for
510 30 min, the flow through discarded and further two 200 μ L washes in 8M urea were
511 performed. Then 100 μ L 0.5 M iodoacetic acid was added for 20 min at room
512 temperature and then centrifuged at 14 000 g for 30 min. The flow-through was
513 discarded. The membrane was washed three times with 100 μ L of 8 M urea,
514 followed by three washes 100 mM TEAB. The lysates were trypsin digested
515 overnight at 37 °C. The digested proteins were eluted in 120 μ L 100mM TEAB. The
516 samples were then desalted using Hypersep Hypercarb™ (ThermoScientific) tips
517 following the manufacturers protocol. Briefly, tips were primed with elution solution
518 (60% Acetonitrile 0.1% TFA) then washed in 0.1% TFA. The sample was then re-
519 suspended on the tip by pipetting up and down 50 times. The tip was cleaned in
520 0.1%TFA, eluted 60% ACN 0.1% TFA and then 90% ACN 0.1% TFA. The samples
521 were then dried down in Speedvac (Eppendorf). The peptides were re-suspended in
522 0.1%TFA and 3% ACN and loaded into and run on Ultimate 3000 RSLC nano flow
523 liquid chromatography system with a PepMap300 C18 trapping column (Thermo
524 Fisher), coupled to Q-Exactive HF Orbitrap mass spectrometer (Thermo Fisher).
525 Peptides were eluted onto a 50 cm x 75 μ m Easy-spray PepMap C18 column with a
526 flow rate of 300 nL/min as previously described (Cole et al. 2019). Peptides were

527 eluted using a gradient of 3% to 35% solvent B over 75 min. Solvents were
528 composed of 0.1% formic acid (FA) and either 3% acetonitrile (ACN) (Solvent A) or
529 80% ACN (Solvent B). The loading solvent was 0.1% TFA and 3% ACN. Data
530 acquisition was performed in full scan positive mode, scanning 375 to 1500m/z, with
531 an MS1 resolution of 120 000, and AGC target of 1×10^6 . The top 10 most intense
532 ions from MS1 scan were selected for Collision induced dissociation. MS2 resolution
533 was of 30 000 with AGC target of 1×10^5 and maximum fill time of 60 ms, with an
534 isolation window of 2 m/z and scan range of 200-2000 m/z and normalised collision
535 energy of 27.

536 **MaxQuant data analysis:**

537 The raw data from the MS were analysed in MaxQuant (version 1.5.6.5). The
538 database search engine Andromeda was used to search the spectra against the
539 UniProt database. The search settings were as follows: trypsin/P digestion, with up to
540 2 miss.ed cleavages, fixed modification was carbamidomethyl (C), variable
541 modifications were oxidation (M) and acetylation (Protein N-term), Label Free
542 Quantification (LFQ) was performed with a minimum number of neighbours of 3 and
543 average number of neighbour of 6. Peptide tolerance was set at 4.5 ppm and minimum
544 peptide length was set at 7, amino acid maximum peptide mass was set at of 4600 Da
545 and Protein FDR was set at 0.01. Downstream analysis was performed in R version
546 3.4.0. The protein identification files were read in, results matching to a reverse
547 sequence database and or those matching to a contaminant database were removed
548 as were those with less than 2 unique peptides. The label-free intensities were then
549 median-corrected for each sample and log2 transformed. Differential protein
550 expression was calculated using Limma version 3.32.2. a repeated measures ANOVA

551 to enable comparison to the microarray analysis (Goeminne, Gevaert, and Clement
552 2016).

553 **Histone extraction:**

554 Histone extraction was performed as previously described (Shechter et al.
555 2007). Briefly, MDMs were washed in PBS and scrapped in ice cold PBS with 1x
556 protease inhibitors (Roche Complete EDTA free), before being pelleted at 900g for 10
557 min. Cell pellets were lysed in hypotonic lysis solution then re-suspended in 400 μ L
558 0.2 M H_2SO_4 . The histones were precipitated out by adding 132uL of 6.1N TCA to the
559 supernatant and washed in acetone then resuspended in 100 μ L of water (HPLC
560 grade). Samples then underwent chemical derivitisation as previously described
561 (Garcia et al. 2007). 10 μ L of 100 mM ammonium bicarbonate pH 8 and 4 μ L of
562 ammonium hydroxide was added to 10 μ g of histone sample. Then 10 μ L of propionic
563 anhydride in isopropanol (1:3 ratio) was added and 100% ammonium hydroxide used
564 to keep the pH >8.0. The sample was incubated at 37°C for 15 min. Then it was dried
565 down in a vacuum centrifuge (Concentrator plus, Eppendorf) and the process
566 repeated. The samples were re-suspended in 40 μ L of 100 mM ammonium
567 bicarbonate and then tryptically digested overnight. The digestion was stopped by
568 addition of glacial acetic acid and freezing at -80°C for 5 min. Finally, the samples
569 were dried down before undergoing a further two rounds of propionylation.
570 Hypersep™ Hypercarb™ tip were used to desalt the samples of the chemical
571 derivitisation residues following the manufacturers protocol for Hypersep™ Hypercarb
572 ™ (ThermoScientific). (Minshull et al. 2016).

573 **Quantitative MS analysis of histone PTMs**

574 The histone samples were re-suspended in 0.1% trifluoroacetic acid (TFA) and
575 were analyzed on an Ultimate 3000 online nano-LC system with a PepMap300 C18

576 trapping column (ThermoFisher Scientific), coupled to a Q Exactive HF Orbitrap
577 (ThermoFisher Scientific). Peptides were eluted onto a 50 cm × 75 µm Easy-spray
578 PepMap C18 analytical column at 35°C. Peptides were eluted at a flow rate of
579 300 nL/min using a gradient of 3% to 25% over 55 min then 25% to 60% until 81 min.
580 Solvents were composed of 0.1% formic acid (FA) and either 3% acetonitrile (ACN)
581 (solvent A) or 80% ACN (solvent B). The loading solvent was 0.1% TFA and 3% ACN
582 run in Data independent acquisition as previously described (Cole et al. 2019). The
583 PTM identification and relative abundance was performed in Skyline and Epiprofile 2.0
584 also as previously described (Cole et al. 2019).

585 **Statistical analysis:**

586 Statistical analysis was performed using either R for the microarray and
587 proteomic analysis, or for all other experiments in Prism version 7.0c (Graphpad). Data
588 is presented as standard deviation (SD) or standard error of the mean (SEM). For all
589 experiments a minimum of 3 biological replicates was used. Comparison between two
590 paired groups employed a paired t-test, for comparison of 3 or more conditions a one-
591 way analysis of variance (ANOVA) with Tukey's post-test was performed. For
592 comparison of multiple observations in more than two groups a two-way ANOVA with
593 Tukey's multiple comparison post-test was performed.

594

595 **References:**

596 Ashburner, Michael, Catherine A. Ball, Judith A. Blake, David Botstein, Heather
597 Butler, J. Michael Cherry, Allan P. Davis, et al. 2000. "Gene Ontology: Tool for
598 the Unification of Biology." *Nature Genetics* 25 (1): 25–29.
599 <https://doi.org/10.1038/75556>.

600 Belchamber, Kylie B. R., Richa Singh, Craig M. Batista, Moira K. Whyte, David H.
601 Dockrell, Iain Kilty, Matthew J. Robinson, Jadwiga A. Wedzicha, Peter J.
602 Barnes, and Louise E. Donnelly. 2019. "Defective Bacterial Phagocytosis Is
603 Associated with Dysfunctional Mitochondria in COPD Macrophages."
604 *European Respiratory Journal*, January.
605 <https://doi.org/10.1183/13993003.02244-2018>.

606 Benton, K A, M P Everson, and D E Briles. 1995. "A Pneumolysin-Negative Mutant
607 of *Streptococcus Pneumoniae* Causes Chronic Bacteremia Rather than Acute
608 Sepsis in Mice." *Infection and Immunity* 63 (2): 448–55.

609 Berger, Shelley L. 2007. "The Complex Language of Chromatin Regulation during
610 Transcription." *Nature* 447 (7143): 407–12.
611 <https://doi.org/10.1038/nature05915>.

612 Bewley, Martin A., Richard C. Budd, Eilise Ryan, Joby Cole, Paul Collini, Jennifer
613 Marshall, Umme Kolsum, et al. 2018. "Opsonic Phagocytosis in Chronic
614 Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists." *American
615 Journal of Respiratory and Critical Care Medicine* 198 (6): 739–50.
616 <https://doi.org/10.1164/rccm.201705-0903OC>.

617 Bewley, Martin A., Michael Naughton, Julie Preston, Andrea Mitchell, Ashleigh
618 Holmes, Helen M. Marriott, Robert C. Read, Timothy J. Mitchell, Moira K. B.
619 Whyte, and David H. Dockrell. 2014. "Pneumolysin Activates Macrophage
620 Lysosomal Membrane Permeabilization and Executes Apoptosis by Distinct
621 Mechanisms without Membrane Pore Formation." *MBio* 5 (5).
622 <https://doi.org/10.1128/mBio.01710-14>.

623 Bolstad, B. M., F. Collin, J. Brettschneider, K. Simpson, L. Cope, R. A. Irizarry, and
624 T.P. Speed. 2005. "Quality Assessment of Affymetrix GeneChip Data." In
625 *Bioinformatics and Computational Biology Solutions Using R and
626 Bioconductor*, edited by Robert Gentleman, Vincent J. Carey, Wolfgang
627 Huber, Rafael A. Irizarry, and Sandrine Dudoit, 33–47. Statistics for Biology
628 and Health. New York, NY: Springer. https://doi.org/10.1007/0-387-29362-0_3.

630 Breuilh, Laetitia, François Vanhoutte, Josette Fontaine, Caroline M. W. van Stijn,
631 Isabelle Tillie-Leblond, Monique Capron, Christelle Faveeuw, et al. 2007.
632 "Galectin-3 Modulates Immune and Inflammatory Responses during
633 Helminthic Infection: Impact of Galectin-3 Deficiency on the Functions of
634 Dendritic Cells." *Infection and Immunity* 75 (11): 5148–57.
635 <https://doi.org/10.1128/IAI.02006-06>.

636 Chen, Guoan, Tarek G. Gharib, Chiang-Ching Huang, Jeremy M. G. Taylor, David E.
637 Misek, Sharon L. R. Kardia, Thomas J. Giordano, et al. 2002. "Discordant
638 Protein and mRNA Expression in Lung Adenocarcinomas." *Molecular &
639 Cellular Proteomics* 1 (4): 304–13. <https://doi.org/10.1074/mcp.M200008MCP200>.

640 Chen, Wei, Mustafa Yazicioglu, and Melanie H. Cobb. 2004. "Characterization of
641 OSR1, a Member of the Mammalian Ste20p/Germinal Center Kinase

643 Subfamily." *Journal of Biological Chemistry* 279 (12): 11129–36.
644 <https://doi.org/10.1074/jbc.M313562200>.

645 Cole, Joby, Eleanor J. Hanson, David C. James, David H. Dockrell, and Mark J.
646 Dickman. 2019. "Comparison of Data-acquisition Methods for the
647 Identification and Quantification of Histone Post-translational Modifications on
648 a Q Exactive HF Hybrid Quadrupole Orbitrap Mass Spectrometer." *Rapid
649 Communications in Mass Spectrometry* 33 (10): 897–906.
650 <https://doi.org/10.1002/rcm.8401>.

651 Cole, Joby, Paul Morris, Mark J. Dickman, and David H. Dockrell. 2016. "The
652 Therapeutic Potential of Epigenetic Manipulation during Infectious Diseases."
653 *Pharmacology & Therapeutics* 167 (November): 85–99.
654 <https://doi.org/10.1016/j.pharmthera.2016.07.013>.

655 Collini, Paul J., Martin A. Bewley, Mohamed Mohasin, Helen M. Marriott, Robert F.
656 Miller, Anna-Maria Geretti, Apostolos Beloukas, et al. 2018. "HIV Gp120 in the
657 Lungs of Antiretroviral Therapy-Treated Individuals Impairs Alveolar
658 Macrophage Responses to Pneumococci." *American Journal of Respiratory
659 and Critical Care Medicine* 197 (12): 1604–15.
660 <https://doi.org/10.1164/rccm.201708-1755OC>.

661 Eskandarian, Haig A, Francis Impens, Marie-Anne Nahori, Guillaume Soubigou,
662 Jean-Yves Coppée, Pascale Cossart, and Mélanie A Hamon. 2013. "A Role
663 for SIRT2-Dependent Histone H3K18 Deacetylation in Bacterial Infection."
664 *Science (New York, N.Y.)* 341 (6145): 1238858.
665 <https://doi.org/10.1126/science.1238858>.

666 Fang, Hai, Bogdan Knezevic, Katie L. Burnham, and Julian C. Knight. 2016. "XGR
667 Software for Enhanced Interpretation of Genomic Summary Data, Illustrated
668 by Application to Immunological Traits." *Genome Medicine* 8 (1): 129.
669 <https://doi.org/10.1186/s13073-016-0384-y>.

670 Fang, Rendong, Kohsuke Tsuchiya, Ikuo Kawamura, Yanna Shen, Hideki Hara,
671 Shunsuke Sakai, Takeshi Yamamoto, et al. 2011. "Critical Roles of ASC
672 Inflammasomes in Caspase-1 Activation and Host Innate Resistance to
673 Streptococcus Pneumoniae Infection." *Journal of Immunology (Baltimore,
674 Md.: 1950)* 187 (9): 4890–99. <https://doi.org/10.4049/jimmunol.1100381>.

675 Garcia, Benjamin A, Sahana Mollah, Beatrix M Ueberheide, Scott A Busby, Tara L
676 Muratore, Jeffrey Shabanowitz, and Donald F Hunt. 2007. "Chemical
677 Derivatization of Histones for Facilitated Analysis by Mass Spectrometry."
678 *Nature Protocols* 2 (4): 933–38. <https://doi.org/10.1038/nprot.2007.106>.

679 Ghazalpour, Anatole, Brian Bennett, Vladislav A. Petyuk, Luz Orozco, Raffi
680 Hagopian, Imran N. Mungrue, Charles R. Farber, et al. 2011. "Comparative
681 Analysis of Proteome and Transcriptome Variation in Mouse." *PLoS Genetics*
682 7 (6). <https://doi.org/10.1371/journal.pgen.1001393>.

683 Goeminne, Ludger J. E., Kris Gevaert, and Lieven Clement. 2016. "Peptide-Level
684 Robust Ridge Regression Improves Estimation, Sensitivity, and Specificity in
685 Data-Dependent Quantitative Label-Free Shotgun Proteomics." *Molecular &
686 Cellular Proteomics* 15 (2): 657–68.
687 <https://doi.org/10.1074/mcp.M115.055897>.

688 Gordon, Stephen B., Glen R. B. Irving, Roderick A. Lawson, Margaret E. Lee, and
689 Robert C. Read. 2000. "Intracellular Trafficking and Killing of Streptococcus
690 Pneumoniae by Human Alveolar Macrophages Are Influenced by Opsonins."
691 *Infection and Immunity* 68 (4): 2286–93.

692 Gray, Barry M., George M. Converse, and Hugh C. Dillon. 1980. "Epidemiologic
693 Studies of Streptococcus Pneumoniae in Infants: Acquisition, Carriage, and
694 Infection during the First 24 Months of Life." *The Journal of Infectious
695 Diseases* 142 (6): 923–33. <https://doi.org/10.1093/infdis/142.6.923>.

696 Hamon, Mélanie Anne, Eric Batsché, Béatrice Régnault, To Nam Tham, Stéphanie
697 Seveau, Christian Muchardt, and Pascale Cossart. 2007. "Histone
698 Modifications Induced by a Family of Bacterial Toxins." *Proceedings of the
699 National Academy of Sciences of the United States of America* 104 (33):
700 13467–72. <https://doi.org/10.1073/pnas.0702729104>.

701 Harvey, Christopher J., Rajesh K. Thimmulappa, Sanjay Sethi, Xiaoni Kong, Lonny
702 Yarmus, Robert H. Brown, David Feller-Kopman, Robert Wise, and Shyam
703 Biswal. 2011. "Targeting Nrf2 Signaling Improves Bacterial Clearance by
704 Alveolar Macrophages in Patients with COPD and in a Mouse Model."
705 *Science Translational Medicine* 3 (78): 78ra32–78ra32.
706 <https://doi.org/10.1126/scitranslmed.3002042>.

707 Houldsworth, S, P W Andrew, and T J Mitchell. 1994. "Pneumolysin Stimulates
708 Production of Tumor Necrosis Factor Alpha and Interleukin-1 Beta by Human
709 Mononuclear Phagocytes." *Infection and Immunity* 62 (4): 1501–3.

710 Hu, Da-Kang, Yang Liu, Xiang-Yang Li, and Ying Qu. 2015. "In Vitro Expression of
711 Streptococcus Pneumoniae Ply Gene in Human Monocytes and
712 Pneumocytes." *European Journal of Medical Research* 20 (1).
713 <https://doi.org/10.1186/s40001-015-0142-4>.

714 Hu, Hongbo, and Shao-Cong Sun. 2016. "Ubiquitin Signaling in Immune
715 Responses." *Cell Research* 26 (4): 457–83.
716 <https://doi.org/10.1038/cr.2016.40>.

717 Jenuwein, T, and C D Allis. 2001. "Translating the Histone Code." *Science (New
718 York, N.Y.)* 293 (5532): 1074–80. <https://doi.org/10.1126/science.1063127>.

719 Jones, Matthew R., Benjamin T. Simms, Michal M. Lupa, Mariya S. Kogan, and
720 Joseph P. Mizgerd. 2005. "Lung NF-KB Activation and Neutrophil Recruitment
721 Require IL-1 and TNF Receptor Signaling during Pneumococcal Pneumonia."
722 *The Journal of Immunology* 175 (11): 7530–35.
723 <https://doi.org/10.4049/jimmunol.175.11.7530>.

724 Kadioglu, Aras, Jeffrey N. Weiser, James C. Paton, and Peter W. Andrew. 2008.
725 "The Role of Streptococcus Pneumoniae Virulence Factors in Host
726 Respiratory Colonization and Disease." *Nature Reviews Microbiology* 6 (4):
727 288–301. <https://doi.org/10.1038/nrmicro1871>.

728 Li, Hua, Sha Wei, Yuan Fang, Min Li, Xia Li, Zhe Li, Jibin Zhang, et al. 2017.
729 "Quantitative Proteomic Analysis of Host Responses Triggered by
730 Mycobacterium Tuberculosis Infection in Human Macrophage Cells." *Acta
731 Biochimica Et Biophysica Sinica* 49 (9): 835–44.
732 <https://doi.org/10.1093/abbs/gmx080>.

733 Li, Pei, Rui Wang, Wenqi Dong, Linlin Hu, Bingbing Zong, Yanyan Zhang, Xiangru
734 Wang, et al. 2017. "Comparative Proteomics Analysis of Human
735 Macrophages Infected with Virulent Mycobacterium Bovis." *Frontiers in
736 Cellular and Infection Microbiology* 7 (March).
737 <https://doi.org/10.3389/fcimb.2017.00065>.

738 Lugrin, Jérôme, Eleonora Ciarlo, Alba Santos, Gaël Grandmaison, Isis dos Santos,
739 Didier Le Roy, and Thierry Roger. 2013. "The Sirtuin Inhibitor Cambinol
740 Impairs MAPK Signaling, Inhibits Inflammatory and Innate Immune

Responses and Protects from Septic Shock." *Biochimica Et Biophysica Acta* 1833 (6): 1498–1510. <https://doi.org/10.1016/j.bbamcr.2013.03.004>.

"Lung NF-KB Activation and Neutrophil Recruitment Require IL-1 and TNF Receptor Signaling during Pneumococcal Pneumonia | The Journal of Immunology." n.d. Accessed April 1, 2020. <https://www.jimmunol.org/content/175/11/7530.long>.

McNeela, Edel A., Áine Burke, Daniel R. Neill, Cathy Baxter, Vitor E. Fernandes, Daniela Ferreira, Sarah Smeaton, et al. 2010. "Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4." *PLoS Pathog* 6 (11): e1001191. <https://doi.org/10.1371/journal.ppat.1001191>.

Minshull, Thomas C., Joby Cole, David H. Dockrell, Robert C. Read, and Mark J. Dickman. 2016. "Analysis of Histone Post Translational Modifications in Primary Monocyte Derived Macrophages Using Reverse Phase×reverse Phase Chromatography in Conjunction with Porous Graphitic Carbon Stationary Phase." *Journal of Chromatography. A* 1453 (July): 43–53. <https://doi.org/10.1016/j.chroma.2016.05.025>.

Pascal, Laura E, Lawrence D True, David S Campbell, Eric W Deutsch, Michael Risk, Ilsa M Coleman, Lillian J Eichner, Peter S Nelson, and Alvin Y Liu. 2008. "Correlation of mRNA and Protein Levels: Cell Type-Specific Gene Expression of Cluster Designation Antigens in the Prostate." *BMC Genomics* 9 (May): 246. <https://doi.org/10.1186/1471-2164-9-246>.

Paton, J. C., B. Rowan-Kelly, and A. Ferrante. 1984. "Activation of Human Complement by the Pneumococcal Toxin Pneumolysin." *Infection and Immunity* 43 (3): 1085–87.

Pee, Katharina van, Alexander Neuhaus, Edoardo D'Imprima, Deryck J Mills, Werner Kühlbrandt, and Özkan Yildiz. 2017. "CryoEM Structures of Membrane Pore and Prepore Complex Reveal Cytolytic Mechanism of Pneumolysin." Edited by Sjors HW Scheres. *eLife* 6 (March): e23644. <https://doi.org/10.7554/eLife.23644>.

Qu, Zehui, Fei Gao, Liwei Li, Yujiao Zhang, Yifeng Jiang, Lingxue Yu, Yanjun Zhou, et al. 2017. "Label-Free Quantitative Proteomic Analysis of Differentially Expressed Membrane Proteins of Pulmonary Alveolar Macrophages Infected with Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus and Its Attenuated Strain." *Proteomics* 17 (23–24). <https://doi.org/10.1002/pmic.201700101>.

Quin, Lisa R., Quincy C. Moore, and Larry S. McDaniel. 2007. "Pneumolysin, PspA, and PspC Contribute to Pneumococcal Evasion of Early Innate Immune Responses during Bacteremia in Mice." *Infection and Immunity* 75 (4): 2067–70. <https://doi.org/10.1128/IAI.01727-06>.

Rogers, P. David, Justin Thornton, Katherine S. Barker, D. Olga McDaniel, Gordon S. Sacks, Edwin Swiatlo, and Larry S. McDaniel. 2003. "Pneumolysin-Dependent and -Independent Gene Expression Identified by CDNA Microarray Analysis of THP-1 Human Mononuclear Cells Stimulated by *Streptococcus pneumoniae*." *Infection and Immunity* 71 (4): 2087–94. <https://doi.org/10.1128/IAI.71.4.2087-2094.2003>.

Rolando, Monica, Serena Sanulli, Christophe Rusniok, Laura Gomez-Valero, Clement Bertholet, Tobias Sahr, Raphael Margueron, and Carmen Buchrieser. 2013. "Legionella Pneumophila Effector RomA Uniquely Modifies Host Chromatin to Repress Gene Expression and Promote Intracellular

791 Bacterial Replication.” *Cell Host & Microbe* 13 (4): 395–405.
792 <https://doi.org/10.1016/j.chom.2013.03.004>.

793 Sander, Leif E., Michael J. Davis, Mark V. Boekschoten, Derk Amsen, Christopher C.
794 Dascher, Bernard Ryffel, Joel A. Swanson, Michael Müller, and J. Magarian
795 Blander. 2011. “Detection of Prokaryotic mRNA Signifies Microbial Viability
796 and Promotes Immunity.” *Nature* 474 (7351): 385–89.
797 <https://doi.org/10.1038/nature10072>.

798 Shechter, David, Holger L. Dormann, C. David Allis, and Sandra B. Hake. 2007.
799 “Extraction, Purification and Analysis of Histones.” *Nature Protocols* 2 (6):
800 1445–57. <https://doi.org/10.1038/nprot.2007.202>.

801 Sloan, Katherine E., Markus T. Bohnsack, and Nicholas J. Watkins. 2013. “The 5S
802 RNP Couples P53 Homeostasis to Ribosome Biogenesis and Nucleolar
803 Stress.” *Cell Reports* 5 (1): 237–47.
804 <https://doi.org/10.1016/j.celrep.2013.08.049>.

805 Stare, Tjaša, Katja Stare, Wolfram Weckwerth, Stefanie Wienkoop, and Kristina
806 Gruden. 2017. “Comparison between Proteome and Transcriptome Response
807 in Potato (*Solanum Tuberosum L.*) Leaves Following Potato Virus Y (PVY)
808 Infection.” *Proteomes* 5 (3): 14. <https://doi.org/10.3390/proteomes5030014>.

809 Starokadomskyy, Petro, Nathan Gluck, Haiying Li, Baozhi Chen, Mathew Wallis,
810 Gabriel N. Maine, Xicheng Mao, et al. 2013. “CCDC22 Deficiency in Humans
811 Blunts Activation of Proinflammatory NF-KB Signaling.” *The Journal of Clinical
812 Investigation* 123 (5): 2244–56. <https://doi.org/10.1172/JCI66466>.

813 Subramanian, Karthik, Daniel R. Neill, Hesham A. Malak, Laura Spelmink, Shadia
814 Khandaker, Giorgia Dalla Libera Marchiori, Emma Dearing, et al. 2019.
815 “Pneumolysin Binds to the Mannose Receptor C Type 1 (MRC-1) Leading to
816 Anti-Inflammatory Responses and Enhanced Pneumococcal Survival.” *Nature
817 Microbiology* 4 (1): 62. <https://doi.org/10.1038/s41564-018-0280-x>.

818 Thimmulappa, Rajesh K., Hannah Lee, Tirumalai Rangasamy, Sekhar P. Reddy,
819 Masayuki Yamamoto, Thomas W. Kensler, and Shyam Biswal. 2016. “Nrf2 Is
820 a Critical Regulator of the Innate Immune Response and Survival during
821 Experimental Sepsis.” *The Journal of Clinical Investigation* 116 (4): 984–95.
822 <https://doi.org/10.1172/JCI25790>.

823 Tweten, Rodney K. 2005. “Cholesterol-Dependent Cytolysins, a Family of Versatile
824 Pore-Forming Toxins.” *Infection and Immunity* 73 (10): 6199–6209.
825 <https://doi.org/10.1128/IAI.73.10.6199-6209.2005>.

826 Walker, J. A., R. L. Allen, P. Falmagne, M. K. Johnson, and G. J. Boulnois. 1987.
827 “Molecular Cloning, Characterization, and Complete Nucleotide Sequence of
828 the Gene for Pneumolysin, the Sulfhydryl-Activated Toxin of *Streptococcus
829 Pneumoniae*.” *Infection and Immunity* 55 (5): 1184–89.

830 Will, Cindy L., Henning Urlaub, Tilmann Achsel, Marc Gentzel, Matthias Wilm, and
831 Reinhard Lührmann. 2002. “Characterization of Novel SF3b and 17S U2
832 SnRNP Proteins, Including a Human Prp5p Homologue and an SF3b
833 DEAD-box Protein.” *The EMBO Journal* 21 (18): 4978–88.
834 <https://doi.org/10.1093/emboj/cdf480>.

835 Wilson, Boris G., and Charles W. M. Roberts. 2011. “SWI/SNF Nucleosome
836 Remodellers and Cancer.” *Nature Reviews Cancer* 11 (7): 481–92.
837 <https://doi.org/10.1038/nrc3068>.

838 Wilson, Claire L., and Crispin J. Miller. 2005. “Simpleaffy: A BioConductor Package
839 for Affymetrix Quality Control and Data Analysis.” *Bioinformatics (Oxford, England)* 21 (18): 3683–85. <https://doi.org/10.1093/bioinformatics/bti605>.

841 Wiśniewski, Jacek R., Alexandre Zougman, Nagarjuna Nagaraj, and Matthias Mann.
842 2009. "Universal Sample Preparation Method for Proteome Analysis." *Nature Methods* 6 (5): 359–62. <https://doi.org/10.1038/nmeth.1322>.
843
844 Zafar, M. Ammar, Yang Wang, Shigeto Hamaguchi, and Jeffrey N. Weiser. 2017.
845 "Host-to-Host Transmission of *Streptococcus pneumoniae* Is Driven by Its
846 Inflammatory Toxin, Pneumolysin." *Cell Host & Microbe* 21 (1): 73–83.
847 <https://doi.org/10.1016/j.chom.2016.12.005>.
848 Zahlten, Janine, Ye-Ji Kim, Jan-Moritz Doebe, Thomas Pribyl, Andreas C. Hocke,
849 Pedro García, Sven Hammerschmidt, Norbert Suttorp, Stefan Hippensiel,
850 and Ralf-Harto Hübner. 2015. "Streptococcus pneumoniae-Induced Oxidative
851 Stress in Lung Epithelial Cells Depends on Pneumococcal Autolysis and Is
852 Reversible by Resveratrol." *The Journal of Infectious Diseases* 211 (11):
853 1822–30. <https://doi.org/10.1093/infdis/jiu806>.
854 Zhao, Hailin, Shiori Eguchi, Azeem Alam, and Daqing Ma. 2017. "The Role of
855 Nuclear Factor-Erythroid 2 Related Factor 2 (Nrf-2) in the Protection against
856 Lung Injury." *American Journal of Physiology - Lung Cellular and Molecular
857 Physiology* 312 (2): L155–62. <https://doi.org/10.1152/ajplung.00449.2016>.
858

859 **Figure legends:**

860 **Figure 1: *S. pneumoniae* induced differential gene expression.**

861 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
862 the isogenic pneumolysin negative mutant (Δ PLY) or mock infected with phosphate
863 buffered saline (MI) in biological replicates of three. After 3 h incubation the gene
864 expression was measured using Affymetrix arrays. A) volcano plots comparing log2
865 (fold change) to log10 p value for MI vs *S. pneumoniae* challenged MDMs. B) volcano
866 plots comparing log2 (fold change) to log10 p value for MI vs Δ PLY challenged MDMs.
867 C) volcano plots comparing log2 (fold change) to log10 p value for *S. pneumoniae* vs
868 Δ PLY challenged MDMs. The probe-sets in blue have a p value <0.05, in red an
869 adjusted p value <0.05 (following FDR correction) and in green an adjusted p value
870 <0.05 and an absolute fold change greater than 1.

871
872 **Figure 2: Oxidative stress response pathway terms significantly upregulated.**

873 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
874 the isogenic pneumolysin negative mutant (Δ PLY) or mock infected with phosphate

875 buffered saline (MI) in biological replicates of three. After 3 h the gene expression was
876 measured using Affymetrix arrays. A) volcano plots comparing log2 (fold change) to
877 log10 p value for MI vs *S. pneumoniae* challenged MDMs. B) volcano plots comparing
878 log2 (fold change) to log10 p value for MI vs Δ PLY challenged MDMs. The highlighted
879 genes belong to the Oxidative stress response Gene Ontology term and are
880 significantly expressed (q value <0.05). In red are those found in challenge with both
881 strains, in blue the genes that are only found in the response to Δ PLY challenge and
882 in orange the pneumolysin-dependent genes found after *S. pneumoniae* but not Δ PLY.

883

884 **Fig 3: Pneumolysin is responsible for changes in relative abundance of PTMs
885 on histone H3.**

886 Monocyte derived macrophages (MDMs) were challenged with either *S.*
887 *pneumoniae*, the isogenic pneumolysin negative mutant (Δ PLY) or mock infected
888 with phosphate buffered saline (MI) in biological replicates of three. After 3 h
889 incubation the histones were extracted and analysed by mass spectrometry and the
890 relative abundance of each post translational modification (PTM) was measured for
891 each peptide. The bar plots represent the relative abundance of each PTM
892 quantified, blue represents the abundance in MI MDMs, green following challenge
893 with *S. pneumoniae* and in red to Δ PLY. A) Peptide TKQTAR shows an increase in
894 the level of H3K4me1. B) Peptide KSTGGKAPR shows a decrease in the level of
895 H3K9me2 in a pneumolysin-dependent manner. C) Peptide KQLATKAAR shows a
896 relative increase in the level of H3K23ac in response to both bacterial challenges. D)
897 Peptide KSAPATGGVKKPHR shows a decrease in H3K27me2 following challenge
898 with *S. pneumoniae* compared to MI, an increase in the level of H3K27me2K36me2
899 and a reciprocal drop in H3K27me3K36me1 in response to Δ PLY challenge

900 compared to MI. E) Peptide EIAQDFKTDLR shows an increase in the relative
901 abundance of H3K79me2 following challenge with Δ PLY. F) Peptide
902 KSAPSTGGVKKPHR of H3.3 shows an increase in H3.3K36me2 and in
903 H3.3K27me2K36me1 with a reciprocal drop in H3.3K27me2K36me2. (One-way
904 ANOVA, * p<0.05, ** p<0.01, *** p<0.001, error bars represent mean and standard
905 deviation).

906
907 **Fig 4: Pneumolysin is responsible for changes in relative abundance of PTMs**
908 **on histone H4.**

909 Monocyte derived macrophages (MDMs) were challenged with either S.
910 *pneumoniae*, the isogenic pneumolysin negative mutant (Δ PLY) or mock infected
911 with phosphate buffered saline (MI) in biological replicates of three. After 3 h
912 incubation the histones were extracted and analysed by mass spectrometry and the
913 relative abundance of each post translational modification (PTM) was measured for
914 each peptide. The bar plots represent the relative abundance of each PTM
915 quantified, blue represents the abundance in MI MDMs, green following challenge
916 with *S. pneumoniae* and in red to Δ PLY. A) Peptide GKGGKGLGKGGAKR shows a
917 relative increase in the level of H4K16ac following challenge with *S. pneumoniae* in
918 comparison to the Δ PLY. B) Peptide KVLR shows a decrease in the level of
919 H4K20me2 in a pneumolysin-dependent manner compared and a reciprocal
920 increase in the H4K20me1. Conversely for the MDM challenged with Δ PLY there
921 was a rise in H4K20me2 and a fall in the level of H4K20me1.(n=3. One way ANOVA,
922 * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).

923
924 **Fig 5: Pneumolysin leads to blunted TNF α release by repressing mRNA**
925 **production.**

926 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
927 the isogenic pneumolysin negative mutant (Δ PLY), the isogenic pneumolysin negative
928 mutant with reconstituted pneumolysin (PLY- Δ PLY), or mock-infected with phosphate
929 buffered saline (MI). A) After 3 h incubation RNA was extracted from MDMs and RT-
930 qPCR performed to measure the abundance of TNF α mRNA. The Bar chart
931 represents the $\Delta\Delta CT$ fold change for each bacterial challenge demonstrating
932 significantly higher abundance of TNF α mRNA following challenge with Δ PLY. One-
933 way ANOVA F statistic =0.01 and p value <0.05. B) At 3 h TNF α concentration were
934 measured in the supernatants of MDMs challenged with each strain. The Bar chart
935 demonstrate the significantly raised level of TNF α in response to challenge with Δ PLY
936 (n=8, one way ANOVA F statistic = 0.0011, p<0.05). C) TNF α and IL-6 cytokines were
937 measured in supernatants following challenge with *S. pneumoniae* or Δ PLY at 0.5, 1,
938 2, 3, 4, 5, 6, 7 h. The bar charts represent mean and Standard Deviation of 3 biological
939 replicates run in technical duplicates are shown demonstrating a significant difference
940 in the rise of TNF- α between the two strains at 4 h, (black line highlights differences
941 between control and Δ PLY, red line between control and *S. pneumoniae*, blue line *S.*
942 *pneumoniae*, and Δ PLY, * p<0.05, ** p<0.01, **** p<0.0001).

943

944 **Fig 6: The HDAC inhibitor Vorinostat suppresses TNF α levels to similar levels
945 as pneumolysin.**

946 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
947 the isogenic pneumolysin negative mutant (Δ PLY) or mock infected with phosphate
948 buffered saline (MI) in the presence of 3 μ M vorinostat (SAHA) or vehicle control (0.5%
949 DMSO). The Bar chart and standard deviation represents the levels of TNF α in the

950 supernatants demonstrating that suppression of TNF α can be mimicked by SAHA to
951 similar levels as in the presence of PLY. (n=7 p<0.05).

952
953 **Supplementary Figure legends:**

954 **Fig S1: Viable intracellular bacteria following 3 h challenge with *S. pneumoniae*,**

955 Δ PLY or PLY- Δ PLY mutants.

956 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
957 the isogenic pneumolysin negative mutant (Δ PLY) or the isogenic pneumolysin
958 negative mutant with reconstituted pneumolysin (PLY- Δ PLY). At 3 h the number of
959 viable intracellular bacteria was determined. The results are expressed as mean and
960 log₁₀ of cfu/mL and represented as bar chart with standard deviation. (n=3, one way
961 ANOVA p=0.99)

962
963 **Fig S2: Heatmap of the differentially expressed probes following MDM**
964 **challenge.**

965 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
966 the isogenic pneumolysin negative mutant (Δ PLY) or mock-infected with phosphate
967 buffered saline (MI) in biological replicates of three. At 3 h the gene expression was
968 measured using Affymetrix arrays. This heatmap represents genes found to be
969 differentially expressed (one-way ANOVA, with F p value <0.05).

970
971 **Fig S3: Gene ontology biological processes enriched terms show stress**
972 **responses and metabolism are over-represented.**

973 Monocyte derived macrophages (MDMs) were challenged with either *S. pneumoniae*,
974 the isogenic pneumolysin negative mutant (Δ PLY) or mock-infected with phosphate
975 buffered saline (MI) in biological replicates of three. At 3 h the gene expression was

976 measured using Affymetrix arrays. The bubble plot shows the top ten enriched Gene
977 Ontology (GO) biological processes terms in both the pneumolysin mutant and the
978 parental strain analysis. The bubble size and colour correspond to the number of
979 genes which have mapped to the GO term. The bubbles are plotted along the x axis
980 according to the $-\log_{10}$ p value for the enrichment.

981

982 **Table S1: Canonical pathway analysis of up-regulated differentially expressed**
983 **probes following challenge of MDMs with *Streptococcus pneumoniae* using**
984 **XGR.**

985 **Table S2: Canonical pathway analysis of up-regulated differentially expressed**
986 **probes following challenge of MDMs with Δ PLY using XGR**

TNF α cytokine level




Figure 6





Figure 4




Figure 3





Figure 2






Figure 1

A)



B)



C)




Figure 5